Iron chelation therapy in the management of thalassemia: the Asian perspectives
- 29 October 2009
- journal article
- review article
- Published by Springer Science and Business Media LLC in International Journal of Hematology
- Vol. 90 (4), 435-445
- https://doi.org/10.1007/s12185-009-0432-0
Abstract
No abstract availableKeywords
This publication has 57 references indexed in Scilit:
- Reduction in labile plasma iron during treatment with deferasirox, a once‐daily oral iron chelator, in heavily iron‐overloaded patients with β‐thalassaemiaEuropean Journal of Haematology, 2009
- Correlation of liver iron concentration determined by R2 magnetic resonance imaging with serum ferritin in patients with thalassemia intermediaHaematologica, 2008
- Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathyExperimental Hematology, 2007
- Serum ferritin underestimates liver iron concentration in transfusion independent thalassemia patients as compared to regularly transfused thalassemia and sickle cell patientsPediatric Blood & Cancer, 2007
- Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbilTranslational Research, 2006
- Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questionsBlood, 2006
- A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemiaBlood, 2006
- LPI-labile plasma iron in iron overloadBest Practice & Research Clinical Haematology, 2005
- ThalassemiaHematology-American Society Hematology Education Program, 2004
- Effectiveness and safety of ICL670 in iron-loaded patients with thalassaemia: a randomised, double-blind, placebo-controlled, dose-escalation trialThe Lancet, 2003